Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James Moreá>
Companies Commented On
- Aastrom Biosciences Inc.
- Achillion Pharmaceuticals Inc.
- Actavis Plc
- Adma Biologics Inc.
- Agenus Inc.
- Alexion Pharmaceuticals Inc.
- Anavex Life Sciences
- Athersys Inc.
- Benitec Biopharma
- BioLineRx Ltd.
- BrainStorm Cell Therapeutics Inc.
- Celgene Corp.
- Cesca Therapeutics Inc.
- Cytori Therapeutics Inc.
- CytRx Corp.
- DelMar Pharmaceuticals Inc.
- Dendreon Corp.
- Gilead Sciences Inc.
- ImmunoCellular Therapeutics Ltd.
- Inovio Pharmaceuticals Inc.
- IsoRay, Inc.
- Medivation Inc.
- Mesoblast Ltd.
- Momenta Pharmaceuticals
- NeoStem Inc.
- Neuralstem Inc.
- Northwest Biotherapeutics Inc.
- Omeros Corp.
- Pfizer Inc.
- Pluristem Therapeutics Inc.
- Roche Holding AG
- Soligenix Inc.
- StemCells Inc.
- Synthetic Biologics Inc.
- Tekmira Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Inc.
Jason Kolbert has worked extensively in the healthcare sector as product manager for a leading pharmaceutical company, as a fund manager and as an equity analyst. Prior to joining Maxim Group, where he is head of healthcare research, senior managing director and biotechnology analyst, Kolbert spent seven years at Susquehanna International Group, where he managed a healthcare fund and founded SIG's biotechnology team. Previously, Kolbert served as the healthcare strategist for Salomon Smith Barney. He is often quoted in the media and is a sought-out expert in the biotechnology field. Prior to beginning his Wall Street career, Kolbert served as a product manager for Schering-Plough in Osaka, Japan. He received a bachelor's degree in chemistry from State University of New York, New Paltz, and a master's degree in business administration from the University of New Haven.
Focus on Catalysts to Cash In on Biotech: Jason Kolbert (6/4/14) When progress is made in drug development, value is created. Investors recognize that progress by purchasing shares in companies when milestonesŚwhich act as catalystsŚare met. The Maxim Group's Senior Managing Director and Head of Healthcare Jason Kolbert lives by catalysts, and urges his investor clientele to understand there is no other reason to buy a stock except in anticipation of new information that creates value. In this interview with The Life Sciences Report, Kolbert discusses six names that have immense regenerative power for portfolios.
How Did High Flyers Turn into Soul Searchers? Maxim Analyst Jason Kolbert on the Highs and Lows of Biotech Valuations (4/2/14) After soaring more than 56% last year, the NASDAQ Biotechnology Index is down almost 15% in March. In this interview with The Life Sciences Report, Jason Kolbert of the Maxim Group points to increased approval rates and a better economic and regulatory environment as the fundamentals behind a revaluation that has occurred in the sector. Kolbert also reflects on recent concerns about pricing and policy changes that have triggered what he considers a normal, healthy correction in an otherwise robust and intact sector.
The New Year Heralds a Transition in Stem Cell Development: Jason Kolbert (12/17/13) The cell therapy industry has been mired in phase 1 and 2 studies for what seems like a lifetime. But 2014 is shaping up to be a banner year for share-moving phase 2 data and pivotal phase 3 activity. Jason Kolbert, managing director for biotechnology research at Maxim Group, leverages his deep understanding of the stem cell space to uncover viable therapies that double as excellent business models. In this interview with The Life Sciences Report, Kolbert guides investors to regenerative medicine companies that have evolved beyond great science projects into businesses capable of generating huge margins and disrupting the paradigm of medical practice.
"Preeclampsia is a very exciting indication, and PSTI has the potential to completely change how we treat this insidious disease." (6/4/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>
"We'd love to see MSB launch a U.S. clinical trial with Prochymal in graft-versus-host disease, where an approved therapy is so desperately needed." (12/17/13) Mesoblast Ltd. - The Life Sciences Report Interview with Jason Kolbert Moreá>
"When you think about the number of opportunities that exist for a company like INO, it's almost limitless." (12/17/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>
"CYTX operates its own subsidiary in Japan, and probably has the largest presence of any cell therapy company in that country." (12/17/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>
"If ATHX can enroll a handful of Japanese patients to be part of the current phase 2 trial, that could create an accelerated pathway to the marketplace." (12/17/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>
"The way that STEM is going about its clinical trials and developing its product and cell line has been brilliant." (5/10/13) StemCells Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>
"CYTX shines because it provides the best of both worlds, an autologous process with allogeneic-like cost of goods sold." (5/10/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>
"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino Moreá>